The University of Osaka · 의학
Hirofumi Yamamoto 교수의 연구실은 간암 및 복강경 비대상 수술 합병증에 대한 임상적 연구와 함께, 암의 치료 저항성과 생존 기전을 규명하는 분자생물학적 연구를 융합하고 있습니다. 특히 KRAS 돌연변이와 관련된 미크로RNA dysregulation, Survivin의 발암성 기전, 그리고 PLOD2와 같은 새로운 예후 생물학적 마커의 역할을 중심으로 암의 분자 기전을 탐구하고 있습니다. 이는 암 치료의 새로운 표적을 제시하고, 개인화된 치료 전략 개발에 기여하고자 하는 목표를 가지고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
PSVT is a more frequent complication of laparoscopic splenectomy than previously reported but can be treated safely following early detection by CT with contrast.
Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favor cancer survival. Many studies on clinical specimens have shown that survivin expression is invariably up-regulated in human cancers and is associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. It is also reported that survivin inhibitio
KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional relevance of miRNAs in mutant KRAS cancers, we transfected exogenous KRAS(G12V) into human embryonic kidney 293 and MRC5 cells with wild-type KRAS and BRAF genes, and we comprehensively profiled the dysregu
PLOD2 is a potential novel prognostic factor for HCC patients following surgery.
